Literature DB >> 16720562

Sinusoidal obstruction syndrome of the liver after hematopoietic stem cell transplantation: decision making for orthotopic liver transplantation.

Christian Koenecke1, Moritz Kleine, Harald Schrem, Utz Krug, Bjoern Nashan, Michael Neipp, Arnold Ganser, Bernd Hertenstein, Juergen Klempnauer.   

Abstract

Sinusoidal obstruction syndrome (SOS) is a specific complication of hematopoietic stem cell transplantation (HSCT) that can lead to substantial morbidity and treatment-related mortality. Heparin is frequently used as prophylaxis of and defibrotide as therapy for mild to moderate SOS. In severe cases of SOS these therapies are often ineffective, and orthotopic liver trans-plantation (OLT) may be the only option. Reports in the literature about the outcome of liver transplantation for SOS are contradictory. We describe our second case of OLT after HSCT. The patient died of intracranial hemorrhage 2 weeks after liver transplantation with good initial organ function. In the first case at our center, however, the patient survived more then 8 years. The reported short- to medium-range survival rate for OLT following HSCT is approximately 50%. On the basis of the experience at our center and the findings in a review of the literature, we developed a rational approach to the selection for liver transplantation of patients with life-threatening liver dysfunction after marrow transplantation.

Entities:  

Mesh:

Year:  2006        PMID: 16720562     DOI: 10.1532/IJH97.NA0511

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  22 in total

1.  Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation.

Authors:  H Hágglund; O Ringdén; B G Ericzon; F Duraj; P Ljungman; B Lönnqvist; J Winiarski; G Tydén
Journal:  Transplantation       Date:  1996-10-27       Impact factor: 4.939

2.  Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial.

Authors:  M Attal; F Huguet; H Rubie; A Huynh; J P Charlet; J L Payen; J J Voigt; P Brousset; J Selves; C Muller
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

3.  Orthotopic liver transplantation for veno-occlusive disease complicating autologous bone marrow transplantation.

Authors:  S Norris; O Crosbie; G McEntee; O Traynor; N Nolan; S McCann; J Hegarty
Journal:  Transplantation       Date:  1997-05-27       Impact factor: 4.939

4.  Hepatic rejection after orthotopic liver transplantation for hepatic veno-occlusive disease or graft-versus-host disease following bone marrow transplantation.

Authors:  A Dowlati; P Honore; P Damas; M Deprez; J Delwaide; G Fillet; Y Beguin
Journal:  Transplantation       Date:  1995-07-15       Impact factor: 4.939

5.  A successful liver transplantation for refractory hepatic veno-occlusive disease originating from cord blood transplantation.

Authors:  Il-Deok Kim; Hiroto Egawa; Yuhji Marui; Satoshi Kaihara; Hironori Haga; Ying-Wei Lin; Kazuko Kudoh; Tetsuya Kiuchi; Shinji Uemoto; Koichi Tanaka
Journal:  Am J Transplant       Date:  2002-09       Impact factor: 8.086

6.  Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant.

Authors:  A P Rapoport; H R Doyle; T Starzl; J M Rowe; T Doeblin; J F DiPersio
Journal:  Bone Marrow Transplant       Date:  1991-11       Impact factor: 5.483

7.  Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors.

Authors:  G B McDonald; P Sharma; D E Matthews; H M Shulman; E D Thomas
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

8.  An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation.

Authors:  H M Shulman; G B McDonald; D Matthews; K C Doney; K J Kopecky; J M Gauvreau; E D Thomas
Journal:  Gastroenterology       Date:  1980-12       Impact factor: 22.682

9.  Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation--clinical and immunological considerations.

Authors:  H J Schlitt; H J Tischler; B Ringe; G Raddatz; H Maschek; H Dietrich; E Kuse; R Pichlmayr; H Link
Journal:  Bone Marrow Transplant       Date:  1995-09       Impact factor: 5.483

10.  Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

Authors:  Paul G Richardson; Carol Murakami; Zhezhen Jin; Diane Warren; Parisa Momtaz; Deborah Hoppensteadt; Anthony D Elias; Joseph H Antin; Robert Soiffer; Thomas Spitzer; David Avigan; Scott I Bearman; Paul L Martin; Joanne Kurtzberg; James Vredenburgh; Allen R Chen; Sally Arai; Georgia Vogelsang; George B McDonald; Eva C Guinan
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

View more
  2 in total

Review 1.  Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Prophylaxis and treatment controversies.

Authors:  Daniel Kl Cheuk
Journal:  World J Transplant       Date:  2012-04-24

2.  Living Donor Liver Transplantation for Hepatic Venoocclusive Disease/Sinusoidal Obstruction Syndrome Originating from Hematopoietic Stem Cell Transplantation.

Authors:  Kentaro Ichimura; Norio Kawamura; Ryoichi Goto; Masaaki Watanabe; Yoshikazu Ganchiku; Tsuyoshi Shimamura; Akinobu Taketomi
Journal:  Case Rep Transplant       Date:  2022-05-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.